Seres Therapeutics, Inc. - 8-K Filing
Seres Therapeutics reports Q3 2026 net loss of $16.3 million and announces plans to submit SER-155 irEC study design to FDA in Q1 2027. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $MCRB